Gornitzky represents the underwriters, led by Oppenheimer & Co., in Intec Pharma’s public offering.
Gornitzky represented the underwriters, led by Oppenheimer & Co., in the USD 37.5 million follow-on offering of Intec Pharma Ltd. on the NASDAQ Capital Market. Intec Pharma is a clinical-stage biopharmaceutical company focused on developing drugs based on its proprietary Accordion Pill platform technology.
Oppenheimer & Co. Inc. acted as sole book-running manager for the offering. Ladenburg Thalmann and Roth Capital Partners acted as co-managers for the offering.